Market capitalization | $5.07b |
Enterprise Value | $4.26b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 5.31 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-307.81m |
Free Cash Flow (TTM) Free Cash Flow | $-203.56m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
14 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:
14 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -2.26 -2.26 |
201%
201%
|
|
EBITDA | -306 -306 |
45%
45%
|
EBIT (Operating Income) EBIT | -308 -308 |
46%
46%
|
Net Profit | -278 -278 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Scott Struthers |
Employees | 290 |
Founded | 2008 |
Website | www.crinetics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.